Document Type

Article

Publication Date

7-22-2023

Comments

This article is the author's final published version in iScience, Volume 26, Issue 18, 18 August 2023, Article number 107375.

The published version is available at https://doi.org/10.1016/j.isci.2023.107375. Copyright © 2023 The Author(s).

Abstract

Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disease with substantial mitochondrial and metabolic dysfunctions. SBMA is caused by polyglutamine (polyQ) expansion in the androgen receptor (AR). Activating or increasing the NAD+-dependent deacetylase, SIRT3, reduced oxidative stress and death of cells modeling SBMA. However, increasing diminished SIRT3 in AR100Q mice failed to reduce acetylation of the SIRT3 target/antioxidant, SOD2, and had no effect on increased total acetylated peptides in quadriceps. Yet, overexpressing SIRT3 resulted in a trend of motor recovery, and corrected TCA cycle activity by decreasing acetylation of SIRT3 target proteins. We sought to boost blunted SIRT3 activity by replenishing diminished NAD+ with PARP inhibition. Although NAD+ was not affected, overexpressing SIRT3 with PARP inhibition fully restored hexokinase activity, correcting the glycolytic pathway in AR100Q quadriceps, and rescued motor endurance of SBMA mice. These data demonstrate that targeting metabolic anomalies can restore motor function downstream of polyQ-expanded AR.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Additional Files
1-s2.0-S2589004223014529-mmc1.pdf (1654 kB)
Document S1. Figures S1–S5
1-s2.0-S2589004223014529-mmc2.xlsx (6621 kB)
Data S1

PubMed ID

37599829

Language

English

Download

Share

COinS